BCYC

Bicycle Therapeutics plc

Price Chart

Latest Quote

$4.04

+0.02 (+0.50%)

Current Price

Previous Close	$4.02
Open	$4.02
Day High	$4.24
Day Low	$4.02
Volume	968,713

Fetched: 2026-06-18T05:42:41

Stock Information

Shares Outstanding	50.37M
Total Debt	$15.34M
Cash Equivalents	$559.47M
Revenue	$63.50M
Net Income	$-219.03M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$282.04M
EPS (TTM)	$-3.15
Exchange	NMS

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$-263.50M
Sales	$63.50M
Income	$-219.03M
Book/sh	$7.95
Cash/sh	$11.11
Employees	288

Financial Ratios

Quick Ratio	12.28
Current Ratio	12.66
Debt/Eq	2.77

Returns & Margins

ROA	-19.38%
ROE	-33.84%
Gross Margin	-244.54%
Operating Margin	-7382.41%

Ownership

Insider Ownership	4.49%
Institutional Ownership	73.65%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-1.90
P/S	4.44
P/B	0.51

Analyst Data

Recommendation	buy
Target Price	$12.62

Technical Indicators

SMA20	$4.30
SMA50	$4.64
SMA200	$6.11
RSI	25.95
ATR	0.2008

Short Float	7.36%
Short Ratio	8.44
Volatility	1.54
Rel Volume	1.78

Performance History

Week	+0.25%
Month	-7.34%
Quarter	-14.04%
6 Months	-44.88%
YTD	-39.52%
Year	-49.75%
3 Years	-84.31%
5 Years	-86.31%
10 Years	-66.33%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-17	$4.04	969,100
2026-06-16	$4.02	947,800
2026-06-15	$4.15	2,982,000
2026-06-12	$4.05	767,600
2026-06-11	$4.10	651,400
2026-06-10	$4.03	238,100
2026-06-09	$4.17	673,300
2026-06-08	$4.11	259,500
2026-06-05	$4.20	479,000
2026-06-04	$4.27	210,000
2026-06-03	$4.20	414,700
2026-06-02	$4.30	320,600
2026-06-01	$4.53	273,700
2026-05-29	$4.69	162,800
2026-05-28	$4.67	116,400
2026-05-27	$4.57	138,800
2026-05-26	$4.57	148,600
2026-05-22	$4.55	304,100
2026-05-21	$4.45	389,400
2026-05-20	$4.42	447,400
2026-05-19	$4.35	365,500
2026-05-18	$4.36	336,800

About Bicycle Therapeutics plc

Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that are in preclinical trial targeting radiopharmaceutical. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; Genentech, Inc; and AstraZeneca AB. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

📰 Latest News

European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading

MT Newswires • 2026-06-17T15:10:44Z

European Equities Traded in the US as American Depositary Receipts Slightly Higher in Tuesday Trading

MT Newswires • 2026-06-16T15:08:44Z

European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading

MT Newswires • 2026-06-02T15:08:08Z

European Equities Traded in the US as American Depositary Receipts Edge Higher in Friday Trading

MT Newswires • 2026-05-22T15:06:28Z

European Equities Traded in the US as American Depositary Receipts Heading Lower in Thursday Trading

MT Newswires • 2026-05-07T15:10:22Z

European Equities Traded in the US as American Depositary Receipts Flat in Friday Trading; Gain 1.3% for Week

MT Newswires • 2026-05-01T15:10:59Z

European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading

MT Newswires • 2026-04-30T15:06:39Z

Morgan Stanley Updates Bicycle Therapeutics plc (BCYC) Outlook Amid Pipeline Refocus

Insider Monkey • 2026-04-17T13:58:42Z

European Equities Traded in the US as American Depositary Receipts Declining in Thursday Trading

MT Newswires • 2026-04-16T15:05:23Z

Wall Street Analysts Believe Bicycle Therapeutics (BCYC) Could Rally 137.88%: Here's is How to Trade

Zacks • 2026-04-16T13:55:02Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$72,586,000	$35,275,000	$26,976,000	$14,463,000
Operating Revenue	$72,586,000	$35,275,000	$26,976,000	$14,463,000
Expenses
Interest Expense	$206,000	$1,730,000	$3,263,000	$3,344,000
Total Expenses	$320,304,000	$244,428,000	$216,922,000	$131,116,000
Other Income Expense	$653,000	$2,803,000	$-594,000	$-555,000
Net Non Operating Interest Income Expense	$28,257,000	$32,554,000	$10,739,000	$2,412,000
Interest Expense Non Operating	$206,000	$1,730,000	$3,263,000	$3,344,000
Operating Expense	$320,304,000	$244,428,000	$216,922,000	$131,116,000
General And Administrative Expense	$80,021,000	$71,462,000	$60,426,000	$49,507,000
Other Non Operating Income Expenses	-	$4,476,000	-	-
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-218,960,000	$-169,031,000	$-180,664,000	$-112,717,000
Net Interest Income	$28,257,000	$32,554,000	$10,739,000	$2,412,000
Interest Income	$28,463,000	$34,284,000	$14,002,000	$5,756,000
Normalized Income	$-219,449,750	$-171,757,150	$-180,664,000	$-112,717,000
Net Income From Continuing And Discontinued Operation	$-218,960,000	$-169,031,000	$-180,664,000	$-112,717,000
Total Operating Income As Reported	$-247,065,000	$-209,872,000	$-189,946,000	$-116,653,000
Net Income Common Stockholders	$-218,960,000	$-169,031,000	$-180,664,000	$-112,717,000
Net Income	$-218,960,000	$-169,031,000	$-180,664,000	$-112,717,000
Net Income Including Noncontrolling Interests	$-218,960,000	$-169,031,000	$-180,664,000	$-112,717,000
Net Income Continuous Operations	$-218,960,000	$-169,031,000	$-180,664,000	$-112,717,000
Pretax Income	$-218,808,000	$-173,796,000	$-179,207,000	$-114,241,000
Special Income Charges	$0	$3,522,000	$0	$0
Interest Income Non Operating	$28,463,000	$34,284,000	$14,002,000	$5,756,000
Operating Income	$-247,718,000	$-209,153,000	$-189,946,000	$-116,653,000
Per Share
Diluted EPS	$-3.16	$-2.90	$-5.08	$-3.80
Basic EPS	$-3.16	$-2.90	$-5.08	$-3.80
Other
Tax Effect Of Unusual Items	$163,250	$76,850	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-212,833,000	$-167,695,000	$-169,398,000	$-107,208,000
Total Unusual Items	$653,000	$2,803,000	$0	$0
Total Unusual Items Excluding Goodwill	$653,000	$2,803,000	$0	$0
Reconciled Depreciation	$6,422,000	$7,174,000	$6,546,000	$3,689,000
EBITDA (Bullshit earnings)	$-212,180,000	$-164,892,000	$-169,398,000	$-107,208,000
EBIT	$-218,602,000	$-172,066,000	$-175,944,000	$-110,897,000
Diluted Average Shares	$69,279,838	$58,207,593	$35,592,362	$29,660,659
Basic Average Shares	$69,279,838	$58,207,593	$35,592,362	$29,660,659
Diluted NI Availto Com Stockholders	$-218,960,000	$-169,031,000	$-180,664,000	$-112,717,000
Tax Provision	$152,000	$-4,765,000	$1,457,000	$-1,524,000
Gain On Sale Of Security	$653,000	$-719,000	$-594,000	$-555,000
Research And Development	$240,283,000	$172,966,000	$156,496,000	$81,609,000
Selling General And Administration	$80,021,000	$71,462,000	$60,426,000	$49,507,000
Other Gand A	$30,223,000	$29,305,000	$60,426,000	$49,507,000
Salaries And Wages	$49,798,000	$42,157,000	$35,881,000	$30,333,000
Other Special Charges	-	$-3,522,000	-	-

Fetched: 2026-06-11

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$609,977,000	$793,060,000	$370,932,000	$270,783,000
Total Assets	$717,597,000	$956,868,000	$595,344,000	$410,609,000
Total Non Current Assets	$34,712,000	$28,263,000	$33,476,000	$41,226,000
Other Non Current Assets	$12,805,000	$11,074,000	$5,792,000	$8,458,000
Current Assets	$682,885,000	$928,605,000	$561,868,000	$369,383,000
Other Current Assets	$19,181,000	$13,432,000	$11,406,000	$9,022,000
Receivables	$35,594,000	$35,653,000	$24,039,000	$21,207,000
Other Receivables	$35,594,000	$35,653,000	$24,039,000	$19,162,000
Cash Cash Equivalents And Short Term Investments	$628,110,000	$879,520,000	$526,423,000	$339,154,000
Cash And Cash Equivalents	$628,110,000	$879,520,000	$526,423,000	$339,154,000
Accounts Receivable	-	-	$0	$2,045,000
Prepaid Assets	-	-	-	-
Cash Financial	-	-	-	-
Debt
Total Debt	$16,852,000	$9,493,000	$44,956,000	$44,325,000
Long Term Debt And Capital Lease Obligation	$14,096,000	$3,990,000	$40,080,000	$41,200,000
Current Debt And Capital Lease Obligation	$2,756,000	$5,503,000	$4,876,000	$3,125,000
Long Term Debt	-	-	$30,698,000	$30,315,000
Liabilities
Total Liabilities Net Minority Interest	$107,620,000	$163,808,000	$224,412,000	$139,826,000
Total Non Current Liabilities Net Minority Interest	$50,636,000	$96,578,000	$154,875,000	$86,484,000
Other Non Current Liabilities	$1,032,000	$1,121,000	$4,579,000	$3,829,000
Non Current Deferred Liabilities	$35,508,000	$91,467,000	$110,216,000	$41,455,000
Current Liabilities	$56,984,000	$67,230,000	$69,537,000	$53,342,000
Other Current Liabilities	$136,000	$297,000	$257,000	$1,472,000
Current Deferred Liabilities	$2,961,000	$10,191,000	$24,978,000	$20,418,000
Payables And Accrued Expenses	$34,131,000	$34,967,000	$26,032,000	$18,399,000
Payables	$9,669,000	$15,793,000	$13,050,000	$6,472,000
Accounts Payable	$9,669,000	$15,793,000	$13,050,000	$6,472,000
Equity
Common Stock Equity	$609,977,000	$793,060,000	$370,932,000	$270,783,000
Total Equity Gross Minority Interest	$609,977,000	$793,060,000	$370,932,000	$270,783,000
Stockholders Equity	$609,977,000	$793,060,000	$370,932,000	$270,783,000
Gains Losses Not Affecting Retained Earnings	$-3,505,000	$119,000	$-1,304,000	$387,000
Other Equity Adjustments	$-3,505,000	$119,000	$-1,304,000	$387,000
Retained Earnings	$-899,751,000	$-680,791,000	$-511,760,000	$-331,096,000
Other
Ordinary Shares Number	$69,367,896	$69,061,418	$42,431,766	$29,873,893
Share Issued	$69,367,896	$69,061,418	$42,431,766	$29,873,893
Tangible Book Value	$609,977,000	$793,060,000	$370,932,000	$270,783,000
Invested Capital	$609,977,000	$793,060,000	$401,630,000	$301,098,000
Working Capital	$625,901,000	$861,375,000	$492,331,000	$316,041,000
Capital Lease Obligations	$16,852,000	$9,493,000	$14,258,000	$14,010,000
Total Capitalization	$609,977,000	$793,060,000	$401,630,000	$301,098,000
Additional Paid In Capital	$1,512,339,000	$1,472,842,000	$883,446,000	$601,105,000
Capital Stock	$894,000	$890,000	$550,000	$387,000
Common Stock	$894,000	$890,000	$550,000	$387,000
Non Current Deferred Revenue	$35,508,000	$91,467,000	$110,216,000	$41,455,000
Long Term Capital Lease Obligation	$14,096,000	$3,990,000	$9,382,000	$10,885,000
Current Deferred Revenue	$2,961,000	$10,191,000	$24,978,000	$20,418,000
Current Capital Lease Obligation	$2,756,000	$5,503,000	$4,876,000	$3,125,000
Pensionand Other Post Retirement Benefit Plans Current	$17,000,000	$16,272,000	$13,394,000	$9,928,000
Current Accrued Expenses	$24,462,000	$19,174,000	$12,982,000	$11,927,000
Net PPE	$21,907,000	$17,189,000	$27,684,000	$32,768,000
Accumulated Depreciation	$-26,178,000	$-18,949,000	$-13,393,000	$-7,863,000
Gross PPE	$48,085,000	$36,138,000	$41,077,000	$40,631,000
Leases	$12,031,000	$10,903,000	$11,000,000	$10,736,000
Other Properties	$34,556,000	$23,364,000	$28,723,000	$28,530,000
Machinery Furniture Equipment	$1,498,000	$1,871,000	$1,354,000	$1,365,000
Properties	$0	$0	$0	$0

Fetched: 2026-06-11

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-252,025,000	$-165,959,000	$-63,557,000	$-105,098,000
Operating Activities
Operating Cash Flow	$-249,675,000	$-164,724,000	$-60,628,000	$-86,111,000
Cash Flow From Continuing Operating Activities	$-249,675,000	$-164,724,000	$-60,628,000	$-86,111,000
Operating Gains Losses	-	$954,000	-	-
Investing Activities
Capital Expenditure	$-2,350,000	$-1,235,000	$-2,929,000	$-18,987,000
Investing Cash Flow	$-2,350,000	$-1,235,000	$-2,929,000	$-18,987,000
Cash Flow From Continuing Investing Activities	$-2,350,000	$-1,235,000	$-2,929,000	$-18,987,000
Financing Activities
Issuance Of Capital Stock	$0	$544,127,000	$249,345,000	$5,703,000
Financing Cash Flow	$-131,000	$519,750,000	$250,027,000	$6,692,000
Cash Flow From Continuing Financing Activities	$-131,000	$519,750,000	$250,027,000	$6,692,000
Net Common Stock Issuance	$0	$544,127,000	$249,345,000	$5,703,000
Common Stock Issuance	$0	$544,127,000	$249,345,000	$5,703,000
Net Preferred Stock Issuance	-	-	-	-
Preferred Stock Issuance	-	-	-	-
Other
Repayment Of Debt	$-168,000	$-31,905,000	$0	$0
Interest Paid Supplemental Data	$78,000	$1,396,000	$2,753,000	$2,793,000
End Cash Position	$628,715,000	$880,067,000	$526,970,000	$339,154,000
Beginning Cash Position	$880,067,000	$526,970,000	$339,154,000	$438,680,000
Effect Of Exchange Rate Changes	$804,000	$-694,000	$1,346,000	$-1,120,000
Changes In Cash	$-252,156,000	$353,791,000	$186,470,000	$-98,406,000
Proceeds From Stock Option Exercised	$37,000	$7,528,000	$682,000	$989,000
Net Issuance Payments Of Debt	$-168,000	$-31,905,000	$0	$0
Net Long Term Debt Issuance	$-168,000	$-31,905,000	$0	$0
Long Term Debt Payments	$-168,000	$-31,905,000	$0	$0
Net PPE Purchase And Sale	$-2,350,000	$-1,235,000	$-2,929,000	$-18,987,000
Purchase Of PPE	$-2,350,000	$-1,235,000	$-2,929,000	$-18,987,000
Change In Working Capital	$-75,751,000	$-33,447,000	$76,663,000	$672,000
Change In Other Working Capital	$-69,190,000	$-31,952,000	$68,951,000	$-2,135,000
Change In Other Current Liabilities	$-5,456,000	$-4,699,000	$-3,600,000	$-1,446,000
Change In Other Current Assets	$4,597,000	$4,402,000	$4,186,000	$2,698,000
Change In Payables And Accrued Expense	$-2,778,000	$12,793,000	$10,400,000	$14,923,000
Change In Accrued Expense	$4,093,000	$9,698,000	$2,398,000	$12,362,000
Change In Payable	$-6,871,000	$3,095,000	$8,002,000	$2,561,000
Change In Account Payable	$-6,871,000	$3,095,000	$8,002,000	$2,561,000
Change In Prepaid Assets	$-5,816,000	$-2,044,000	$-2,072,000	$-2,020,000
Change In Receivables	$2,892,000	$-11,947,000	$-1,202,000	$-11,348,000
Changes In Account Receivables	$0	$0	$2,482,000	$-1,641,000
Stock Based Compensation	$39,464,000	$38,081,000	$32,477,000	$26,779,000
Deferred Tax	$-850,000	$-5,226,000	$3,306,000	$-4,976,000
Deferred Income Tax	$-850,000	$-5,226,000	$3,306,000	$-4,976,000
Depreciation Amortization Depletion	$6,422,000	$7,174,000	$6,546,000	$3,689,000
Depreciation And Amortization	$6,422,000	$7,174,000	$6,546,000	$3,689,000
Net Income From Continuing Operations	$-218,960,000	$-169,031,000	$-180,664,000	$-112,717,000
Income Tax Paid Supplemental Data	-	$792,000	$562,000	$2,228,000
Other Non Cash Items	-	$-3,229,000	$1,044,000	$442,000
Issuance Of Debt	-	-	$0	$0
Long Term Debt Issuance	-	-	$0	$0

Fetched: 2026-06-11